I suspect that as the company have at this time indicated they are not going to be releasing any more cheap shares the big buyers now have to buy them at the normal price. I noticed there were a number of large trades 100,000 + which is possibly the MMs returning to this share.

It will be interesting to see how it goes next week. They were at around 6p only a few weeks ago without any real news so there is scope. More important will be if any news come out prior to the trial results about either acquisitions or partnership deals. It seems at present that Percy Lomax wants to broaden the company a bit by acquisition. It's a risk but once such news comes out the shares will probably rocket.

I bought in around 3p so have had to hold my nerve over the last couple of weeks but I know of others much wiser than me who bought in at the 5- 6p level and are still confident.

We shall see but good luck if you're in.

I bought in at 3p and with todays rise I am just about even but as you say I will continue to hold for the 5p level..also MMG from 6p and they are now 42p today..

Consider that Regen are coming towards the end of phase 2 trials in their Colostrinin/ Alzheimers treatment- I believe they should complete in early 2004.Phase 2A is already done and 2B I think will be early 2004 so phase 3 should start in 2004. then look at Phytopharm info below but as always dyor

From Regen

News Centre

ColostrininTM Clinical Study to be published in Journal of Alzheimer's Disease 8/10/2003

ReGen Therapeutics Plc ('ReGen' or the 'Company'), a company developing a potential treatment for Alzheimer's disease, announces that a manuscript reviewing the full results of its clinical study RG-010 has been accepted in its final form for publication in the Journal of Alzheimer's Disease (the 'Journal'). The publishers of the Journal advise that the article will appear in their February 2004 edition.

Interesting news from elsewhere - Phytopharm

I copied the info below from another site post but it demonstrates the enormous earning potential here if Phytopharm are only just completing stage 1 and already have 33 million on the table.

Regen might be a smaller outfit but they seem to be well ahead and at 3p the price is a bit more atractive but dyor. I've also copied part of Regens info below for comparison.


Phytopharm completes successful clinical study
AFX
Another milestone in the fight against Alzheimer's



Phytopharm PLC said it has successfully completed a phase Ib clinical study of its orally active synthetic neuroprotective and neuroregenerative product, PYM50028, which is under development as a treatment for a range of neurological disorders, including Alzheimer's and Parkinson's diseases.

Phytopharm said the data is the subject of a second milestone payment from Yamanouchi Pharmaceutical Co Ltd, with whom it has a licence agreement for marketing of PYM50028 in Japan and some other Asian countries.

A total of 33 mln usd in milestones was specified in the agreement, subject to the achievement of specific objectives, of which 17 mln usd will be potentially payable to Phytopharm over the next 18 months; it will also receive royalties on the sale of PYM50028.

In the study, thirty healthy men and women aged 50 years and older were enrolled and randomly allocated to receive either PYM50028 or placebo once daily for 28 days.

Results indicate that the product has absorption and pharmacokinetic characteristics suitable for once-daily dosing and is well tolerated with a good emergent safety profile.

A phase II clinical study in Alzheimer's patients is now anticipated to begin shortly, during which PYM50028 will be compared with placebo over a three-month dosing period.

'We are making rapid progress in the development of PYM50028 and are encouraged with the dosing profile of this product,' chief executive Dr Richard Dixey said.

Phytopharm, which develops plant-based pharmaceuticals, said PYM50028 arose from research into the activity of an Asian medicinal plant.




+++++++++++++
http://www.regentherapeutics.com/regen/EditHistory.shtml
+++++++++++++

Company Overview

Recent Achievements and Future Strategy

ReGen Therapeutics Plc was founded in 1998 to develop a treatment for Alzheimer’s disease using Colostrinin™, a product derived from ovine colostrum. Since its foundation, ReGen has achieved a number of significant milestones, but the key one was certainly the successful outcome to the clinical trials using Colostrinin™ in the summer of 2002. Encouraged by the positive findings from the trials and following a widespread review of our ongoing strategy, the project has been carried forward since the beginning of 2003 in a number of ways:

* Significant progress has been made towards identifying the Mode of Action of Colostrinin™.
* New potency assays are in development, which may better represent the clinical activity of Colostrinin™. These assays are important in both the finalisation of a manufacturing process and in the assessment of whether increasing the dose of Colostrinin™ might lead to a better clinical response, whilst maintaining the clean safety profile seen so far.
* We are now well advanced with the development of a more controllable and more efficient manufacturing process, which we believe can be more easily adapted to an industrial scale. We have shown that Colostrinin™ made by the new process and using standardised bovine colostrum is physico-chemically the same as that made by the original process using ovine colostrum. We are currently testing the new preparations for biological activity, using the new assays and laboratory models.
* Our initial assessment that Colostrinin™ might have potential as a nutraceutical, in addition to its application as a pharmaceutical, has been supported by the results of an independent review. Further development of these plans is continuing.
* A better understanding of the Mode of Action has suggested several other disease areas, in addition to Alzheimer’s disease, where Colostrinin™ might be effective. It is anticipated that a general proteomics analysis of Colostrinin™ and an early stage screen to assess its anti-cancer activity will commence in mid-2003.
Raising cash sufficient for the funding requirements of the Company continues to be difficult in the current stock market climate. Nonetheless, between December 2002 and June 2003, we have been able to raise 395,000 through a broker-placing of new equity and have realised 125,000 through selling part of our investment trust portfolio. We continue to be innovative in our funding.
In addition to continuing to develop the core Colostrinin™ project, we are also looking to acquire other private companies which are or are capable of being profitable. There are a number of attractive businesses around and we believe that adding additional “legs” to the Company makes it a safer and more attractive investment in the future.
ReGen has come a long way in the four years since its IPO in December 1998. Our vision is that by December 2006 we will have a profitable and fully listed UK-based drug company.
History
ReGen therapeutics Plc was formed in February 1998 to acquire intellectual property rights from the Ludwik Hirszfeld Institute of Immunology & Experimental Therapy in Wroclaw Poland to develop a polypeptide complex derived from colostrum and branded under the name Colostrinin™. This peptide complex is viewed as a potential therapy for a number of human conditions particularly Alzheimer’s disease.
Trials using Colostrinin™, carried out in Poland dating back to 1995, had indicated a significant potential benefit to Alzheimer’s disease sufferers. Following acquisition of the intellectual property rights, ReGen embarked on a programme to develop the therapy, with the intention to pursue the registration of Colostrinin™ as a pharmaceutical drug and bring it to market as quickly as possible.
ReGen’s shares were admitted to trading on the London OFEX market in November 1998, following a successful 1.45 million fund-raising. An additional 0.3 million of interim funding was raised following a share placing a year later and in March 2000 5.0 million was raised through a further issue of equity, at which point the Company’s shares moved to being traded on the Alternative Investment Market of the London Stock Exchange. Additional funding, amounting to over 2.6 million, was raised during the intervening period to May 2003, through the issue of equity to new and existing shareholders. The Company also has access to potential funding for the future via shareholdings in two investment trusts, both of whom are listed on the London Stock Exchange.
With regard to the continued clinical development of Colostrinin™, ReGen conducted a formal placebo-controlled clinical trial on Alzheimer’s sufferers in Poland, which completed in mid-2002. Results from the trial showed 33% of patients achieved stabilisation or improvement in their disease condition after 30 weeks of treatment, with efficacy demonstrated in both mild and moderate symptom groups. The previously observed good safety profile continued, with no Serious Adverse Events or other safety concerns being seen. The outcome of this trial is considered by the Company to be very positive and confirms its view that Colostrinin continues to offer a potentially very effective treatment for Alzheimer's disease.
In addition to the continued scientific development being carried out in the UK, the Company has a number of collaborators world-wide, including an important long term relationship with the University of Texas Medical Branch in Galveston, Texas, USA (UTMB), whose scientists are conducting much of the ongoing work on Mode of Action. Important research into other aspects of the Colostrinin™ project is also being conducted by the Roswell Park Cancer Institute in the US and the Open University, Milton Keynes and St. Georges Hospital, Tooting in the UK.
Finally, the lifeblood of a Company of ReGen’s type, size and ambition is it’s intellectual property portfolio. A substantial number of patent applications have already been filed with various patent authorities throughout the World and further applications will be made as the Company continues to develop its technology. Many of these patents are particularly targeted at protecting discoveries in the field of the treatment of Alzheimer’s disease, but many have potentially wider applications and may, if granted, allow the Company’s expansion into the development of other therapies in the future. Most of the Company’s patent applications are in the process of examination by the various patent offices, but up to mid-2003, the Company has had one of its patents granted in the United Kingdom and South Africa, another (under licence from UTMB) granted in the USA and its subsidiary, ReGen Biotech Ltd had a patent on the use of Colostrinin™ in combination with other materials as a dietary supplement granted in the UK in October 2002.


If you've got this far - well done and good luck with Regen

Regards

Gantenbrink

20% up today. Pleased as I was I couldn't work out why but have now read:-

http://www.thisismoney.com/20040109/nm72725.html

If Pfizer really is interested in backing Regen then it is really good news for those who have been patiently holding.

I didnt know that phizer were interested but its great news if its true..

Checked this out with Percy Lomax today and there doesn't seem to be anything in it. He is talking to some big names but at present Pfizer doesn't seem to be one. My guess is that he won't finalise a licensing deal until production is sorted around the summer.

The good news is that he is being contacted by a number of institutional investors who are looking at advising clients to get involved. I don't think we've seen any of this money yet as no large trades. However the small trades are mounting and with this momentum and price increase with luck some of the bigger players will get involved.

I attended the conference just before Christmas and was encouraged at the number of private investors with reasonble size holdings who are all in for the long term. With a big chunk of stock like that not coming to the market hopefully it will create a shortage as more buyers appear and that in itself will push up the price.

All this aside from the fact that the potential value of Collostinin as a pharmaceutical product is massive.

For those already in, I think it worth holding on as impressive news are on the way.

Neutral (Medium term) - Jan 12, 2004
Has risen 271% since the bottom on 2 Apr 2003 at 0.88. Has broken up from an approximate horizontal trend. This signals a continued strong development, and the stock now meets support on possible reactions down towards the ceiling of the trend channel. The stock has support at p 2.34 and resistance at p 6.40. Poor liquidity (traded 100% of the days, mean 6.12 mill per day) weakens the analysis.

Do have RGT on my monitor.

Best Wishes,

Sue.

I make volume about twice as many buys and sells and would have thought that all trades should be in by now. Transactions seemed to be about 11 buyers to every seller. Strange that price dropped this afternoon- hopefully just a market maker treeshake but it didn't seem to work.

Good news that there is this sort of volume for the day as at least we're active and hopefully we have lost the profit takers along the way without the price dropping back too much.

Hopefully tomorrow my be a very fruitful day seeing that my screen still showed reasonably large buys going through at the end of the day 2x250k 1x190k